BOS-318是一种具有细胞渗透性的、高效且高选择性的弗林蛋白酶（furin；IC50=1.9nM）抑制剂。
Cas No.:2387633-15-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
BOS-318 is a cell-permeable, potent, and highly selective inhibitor of furin (IC50=1.9nM)[1-2]. BOS-318 is applicable for research in cystic fibrosis (CF) lung disease and can serve as an adjunctive therapy to CFTR modulators such as ETI[3-4].
In vitro, treatment of differentiated cystic fibrosis human bronchial epithelial cells (CF HBECs) with BOS-318 (0.3µM) for 2 or 48 hours significantly inhibited epithelial sodium channel (ENaC)-mediated sodium absorption. A 2- or 48-hour pretreatment of CF HBECs with BOS-318 (0.3µM), followed by stimulation with neutrophil elastase (NE; 2.5µg/mL) or CF sputum supernatant. BOS-318 protected ENaC from activation by NE. Treatment of CuFi-1 cells with BOS-318 (0.001–1µM) for 72 hours conferred dose-dependent protection against Pseudomonas aeruginosa exotoxin A (PEA; 500ng/mL)-mediated cytotoxicity[5]. In BRAF-mutated human melanoma cell lines (A375M6 and M21), a 24-hour treatment with BOS-318 (5nM) reduced the expression of TGFβ1 and phosphorylated SMAD2. When combined with pirfenidone (8.1mM), BOS-318 synergistically increased p21 expression and elevated the proportion of cells entering late apoptosis[6].
In vivo, in a mouse model of acute lung injury induced by Pseudomonas aeruginosa (PA103) or exotoxin A (Exo-A), a single administration of BOS-318 (5mM; i.p.; 200µL; and 0.874mM; intratracheal; 50µL) 1 hour prior to infection significantly improved survival at 96 hours post-infection, attenuated hypothermia and body weight loss, reduced protein and inflammatory cytokine levels in bronchoalveolar lavage fluid (BALF), and accelerated bacterial clearance[7]. In adult C57BL/6 mice, a single oral dose of BOS-318 (10mg/kg) administered 24 hours before electrophysiological experiments. BOS-318 significantly inhibited furin activity in tissues and prevented the PAR1 agonist TFLLR-NH2-induced potentiation of neuromuscular transmission[8].
References:
[1] Douglas LEJ, Reihill JA, Martin SL. BOS-318 treatment enhances elexacaftor-tezacaftor-ivacaftor-mediated improvements in airway hydration and mucociliary transport. ERJ Open Res. 2025 Feb 25;11(1):00445-2024.
[2] Nayak D, Wasmuth EV, Olsen SK. Clearing the air: Uniquely engaging furin as an approach to cystic fibrosis therapy. Cell Chem Biol. 2022 Jun 16;29(6):927-929.
[3] Ducrocq GP, Anselmi L, Stella SL Jr, et al. Inhibition and potentiation of the exercise pressor reflex by pharmacological modulation of TRPC6 in male rats. J Physiol. 2025 Sep;603(18):5027-5052.
[4] Ridgway H, Orbell JD, Matsoukas MT, et al. W254 in furin functions as a molecular gate promoting anti-viral drug binding: Elucidation of putative drug tunneling and docking by non-equilibrium molecular dynamics. Comput Struct Biotechnol J. 2023 Sep 9;21:4589-4612.
[5] Douglas LEJ, Reihill JA, Ho MWY, et al. A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway disease. Cell Chem Biol. 2022 Jun 16;29(6):947-957.e8.
[6] Marchese M, La Regina G, Amato R, et al. The unexplored mechanism of antitumoral effect of pirfenidone in melanoma cells. Sci Rep. 2025 Aug 1;15(1):28071.
[7] Bernard O, Kwon M, Looney MR, et al. Furin Inhibition Protects Against Acute Lung Injury in a Mouse Model of Pseudomonas Aeruginosa Infection. Am J Respir Cell Mol Biol. 2026 Feb 15:aanag024.
[8] Molchanova, A.I., Shepelev, E.I., Gaydukov, A.E. PAR1-Mediated Retrograde Action of Brain-Derived Neurotrophic Factor and Its Prodomain in Mature Mouse Motor Synapses is Provided by Furin Activity. Neurochem J. 2025; 19: 717–727.
BOS-318是一种具有细胞渗透性的、高效且高选择性的弗林蛋白酶（furin；IC50=1.9nM）抑制剂[1-2]。BOS-318可用于囊性纤维化（CF）肺病的研究，并可作为CFTR调节剂疗法（如ETI）的辅助治疗手段[3-4]。
在体外，BOS-318（0.3μM）处理分化的囊性纤维化人气道上皮细胞（CF HBECs）2小时或48小时，可显著抑制上皮钠通道（ENaC）介导的钠离子吸收。BOS-318（0.3μM）预处理CF HBECs 2小时或48小时，随后以中性粒细胞弹性蛋白酶（NE；2.5μg/mL）或CF痰液上清刺激。BOS-318可保护ENaC免受NE的激活。BOS-318（0.001–1μM）处理CuFi-1细胞72小时，可剂量依赖性地保护细胞免受铜绿假单胞菌外毒素A（PEA；500ng/mL）介导的细胞毒性[5]。BOS-318（5nM）处理BRAF突变的人黑色素瘤细胞系（A375M6和M21）24小时。BOS-318能够降低TGFβ1和磷酸化SMAD2的表达；当与吡非尼酮（8.1mM）联合处理时，BOS-318可协同增加p21表达，提高进入晚期凋亡的细胞比例[6]。
在体内，BOS-318在感染前1小时单次给药（5mM；腹腔注射；200μL；及0.874mM；气道内给药；50μL）于铜绿假单胞菌（PA103）或外毒素A（Exo-A）诱导的小鼠急性肺损伤模型中，可显著提高感染后96小时的生存率，减轻体温下降和体重减轻，降低支气管肺泡灌洗液（BALF）中的蛋白和炎性细胞因子水平，并加速体内细菌清除[7]。BOS-318（10mg/kg）在电生理实验前24小时单次口服给予成年C57BL/6小。BOS-318能够显著抑制组织中的弗林蛋白酶活性，并阻止PAR1激动剂TFLLR-NH2对神经肌肉传递的增强作用[8]。
| Cell experiment [1]: | |
Cell lines | A375M6 and M21 human BRAF-mutated melanoma cell lines |
Preparation Method | Melanoma cells were cultured in DMEM supplemented with 10% FBS. Cells were exposed to BOS-318 (5nM) and/or pirfenidone (PFD) for 24 hours in complete standard medium. |
Reaction Conditions | 5μM; 24h. |
Applications | BOS-318 treatment reduced the expression of TGFβ1 and phospho-SMAD2. When combined with pirfenidone (8.1mM), BOS-318 synergistically increased p21 expression and raised the proportion of cells entering late apoptosis. |
| Animal experiment [2]: | |
Animal models | Adult C57BL/6 mice of both sexes |
Preparation Method | Mice were administered a single oral dose of BOS-318 (10mg/kg) 24 hours before electrophysiological experiments. Administration was performed by voluntary swallowing using a standard replaceable tip and an automatic pipette, with a maximum volume of 100µL of the solution. |
Dosage form | 10mg/kg; oral administration; single dose. |
Applications | Oral administration of BOS-318 significantly inhibited furin activity in tissues and prevented the PAR1 agonist TFLLR-NH2-induced potentiation of neuromuscular transmission. |
References: | |
| Cas No. | 2387633-15-8 | SDF | Download SDF |
| 分子式 | C28H32Cl2N6O3 | 分子量 | 571.5 |
| 溶解度 | DMSO : 50 mg/mL (87.49 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7498 mL | 8.7489 mL | 17.4978 mL |
| 5 mM | 350 μL | 1.7498 mL | 3.4996 mL |
| 10 mM | 175 μL | 874.9 μL | 1.7498 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet